✦ LIBER ✦

PCN90 Cost-Effectiveness Analysis of Erlotinib Versus Docetaxel, Pemetrexed for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Russia

✍ Scribed by Nguyen, T.T.T.; Yagudina, R.; Kulikov, A.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLO

✍ TC Hsia; GC Chang; YM Chen; MC Lin; WC Su; CM Tsai; CM Tsai; L Yang; J Creeden 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PCN25 COST-EFFECTIVENESS ANALYSIS OF ERL

✍ Kim, YG; Lee, EK 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PCN37 Cost Comparison of Erlotinib Versu

✍ Schwander, B.; Ravera, S.; Giuliani, G.; Nuijten, M.; Walzer, S. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PCN50 COST-MINIMIZATION ANALYSIS OF ERLO

✍ E Suchankova; T Doležal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

Cost-effectiveness analysis of pemetrexe

✍ Yumi Asukai; Amparo Valladares; Carlos Camps; Eifiona Wood; Kaisa Taipale; Jorge 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 781 KB

PCN10 COSTS OF MANAGING TOXICITIES IN AD

✍ M Aristides; D Jackson; AM Liepa; NB Leighl; F Shepherd 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB